96 related articles for article (PubMed ID: 19815259)
1. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
Caire AA; Sun L; Robertson CN; Polascik TJ; Maloney KE; George DJ; Price MM; Stackhouse DA; Lack BD; Albala DM; Moul JW
Urology; 2010 May; 75(5):1122-7. PubMed ID: 19815259
[TBL] [Abstract][Full Text] [Related]
2. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
4. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
7. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
8. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
9. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
11. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
D'Amico AV; Chen MH; Catalona WJ; Sun L; Roehl KA; Moul JW
Cancer; 2007 Jul; 110(1):56-61. PubMed ID: 17530618
[TBL] [Abstract][Full Text] [Related]
13. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Weinstein M; Tomaszewski JE; Schultz D; Rhude M; Rocha S; Wein A; Richie JP
J Urol; 2001 Dec; 166(6):2185-8. PubMed ID: 11696732
[TBL] [Abstract][Full Text] [Related]
14. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
[TBL] [Abstract][Full Text] [Related]
15. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
16. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
[TBL] [Abstract][Full Text] [Related]
17. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
Xu DD; Sun SD; Wang F; Sun L; Stackhouse D; Polascik T; Albala DM; Moul JW; Caire A; Robertson CN
Urology; 2009 Sep; 74(3):654-8. PubMed ID: 19628263
[TBL] [Abstract][Full Text] [Related]
18. Predictors of prostate cancer screening among health fair participants.
Chiu BC; Anderson JR; Corbin D
Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
[TBL] [Abstract][Full Text] [Related]
19. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
Caire AA; Sun L; Ode O; Stackhouse DA; Maloney K; Donatucci C; Mouraviev V; Polascik TJ; Robertson CN; Albala DM; Moul JW
Urology; 2009 Sep; 74(3):643-7. PubMed ID: 19501891
[TBL] [Abstract][Full Text] [Related]
20. Behavioral associations between prostate and colon cancer screening.
Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
